{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:13:50Z","timestamp":1762866830876,"version":"3.32.0"},"reference-count":0,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"vor","delay-in-days":1005,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Infectious Diseases and Medical Microbiology"],"published-print":{"date-parts":[[1998,1]]},"abstract":"<jats:p>OBJECTIVE: To compare the activity of piperacillin\/tazobactam with that of other broad parenteral antibiotics against aerobic and facultative anaerobic blood culture isolates in a Canada\u2010wide survey.<\/jats:p><jats:p>DESIGN: Fifty\u2010eight laboratories in nine provinces each contributed up to 50 consecutive clinically significant aerobic and facultative anaerobic isolates for susceptibility testing.<\/jats:p><jats:p>SETTING: Participating hospitals included both tertiary care and community hospitals.<\/jats:p><jats:p>MATERIALS AND METHODS: Testing was performed in five regional centres by using the same microbroth dilution method, and results were interpreted according to National Commitee for Clinical Laboratory Standards M7\u2010A3 and M100\u2010S5 guidelines.<\/jats:p><jats:p>RESULTS: Piperacillin\/tazobactam and imipenem were both active against more than 99% of the 1616 strains of <jats:italic>Enterobacteriaceae<\/jats:italic> species tested. The minimum inhibitory concentration of 90% of isolates (MIC<jats:sub>90<\/jats:sub>) of all <jats:italic>Enterobacteriaceae<\/jats:italic> species was 2\u2009mg\/L for piperacillin\/tazobactam compared with 64\u2009mg\/L for piperacillin alone. Seventeen per cent of strains of <jats:italic>Enterobacteriaceae<\/jats:italic> species were susceptible to piperacillin\/tazobactam but resistant to piperacillin. Piperacillin\/tazobactam was highly active against <jats:italic>Pseudomonas aeruginosa<\/jats:italic>, inhibiting 99.1% of strains. MIC<jats:sub>90<\/jats:sub> was 8\u2009mg\/L. Nine per cent of <jats:italic>P aeruginosa<\/jats:italic> strains were not susceptible to imipenem. Most of these strains had a MIC of 8\u2009mg\/L, which falls in the intermediate category. Ninety\u2010seven per cent of <jats:italic>P aeruginosa<\/jats:italic> were susceptible to ciprofloxacin and 97.3% to tobramycin. Ninety\u2010six per cent of strains of <jats:italic>Actinobacter<\/jats:italic> species were susceptible to piperacillin\/tazobactam, whereas only 76% of strains were susceptible to piperacillin alone. Overall, piperacillin\/tazobactam was the most active agent tested; 98% of all strains were susceptible, followed closely by imipenem, to which 97.8% of strains were susceptible.<\/jats:p><jats:p>CONCLUSIONS: Aerobic blood culture isolates from Canadian centres continue to be highly susceptible to a variety of antibiotics. The broad spectrum of activity of piperacillin\/tazobactam suggests that this combination should be considered for empirical treatment of sepsis while awaiting results of cultures and susceptibility testing.<\/jats:p>","DOI":"10.1155\/1998\/730838","type":"journal-article","created":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T13:52:08Z","timestamp":1458049928000},"page":"33-44","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cross\u2010Canada Survey of Resistance of 2747 Aerobic Blood Culture Isolates to Piperacillin\/Tazobactam and Other Antibiotics"],"prefix":"10.1155","volume":"9","author":[{"given":"Kevin R","family":"Forward","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia A","family":"Franks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald E","family":"Low","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Rennie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew E","family":"Simor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"the Canadian Piperacillin\/Tazobactam Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[1997,4]]},"container-title":["Canadian Journal of Infectious Diseases and Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/cjidmm\/1998\/730838.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/1998\/730838","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T05:02:41Z","timestamp":1735621361000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/1998\/730838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,4]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1998,1]]}},"alternative-id":["10.1155\/1998\/730838"],"URL":"https:\/\/doi.org\/10.1155\/1998\/730838","archive":["Portico"],"relation":{},"ISSN":["1712-9532","1918-1493"],"issn-type":[{"type":"print","value":"1712-9532"},{"type":"electronic","value":"1918-1493"}],"subject":[],"published":{"date-parts":[[1997,4]]},"assertion":[{"value":"1997-01-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1997-04-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}